Eisai Completes Submission of LEQEMBI ® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Posted from: this blog via Microsoft Power Automate.